MDT

88.85

+1.62%↑

VEEV

279.31

-1.23%↓

A

121.78

+3.12%↑

WBA

11.5

-0.26%↓

HQY

102.44

+1.94%↑

MDT

88.85

+1.62%↑

VEEV

279.31

-1.23%↓

A

121.78

+3.12%↑

WBA

11.5

-0.26%↓

HQY

102.44

+1.94%↑

MDT

88.85

+1.62%↑

VEEV

279.31

-1.23%↓

A

121.78

+3.12%↑

WBA

11.5

-0.26%↓

HQY

102.44

+1.94%↑

MDT

88.85

+1.62%↑

VEEV

279.31

-1.23%↓

A

121.78

+3.12%↑

WBA

11.5

-0.26%↓

HQY

102.44

+1.94%↑

MDT

88.85

+1.62%↑

VEEV

279.31

-1.23%↓

A

121.78

+3.12%↑

WBA

11.5

-0.26%↓

HQY

102.44

+1.94%↑

Search

Roivant Sciences Ltd

Отворен

СекторЗдравеопазване

10.85 0.84

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.7

Максимум

10.93

Ключови измерители

By Trading Economics

Приходи

-278M

-252M

Продажби

-1.4M

7.6M

EPS

-0.218

Марж на печалбата

-3,333.884

Служители

750

EBITDA

-9.2M

-284M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+36.49% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

68M

7.7B

Предишно отваряне

10.01

Предишно затваряне

10.85

Настроения в новините

By Acuity

50%

50%

143 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Roivant Sciences Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.07.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7.07.2025 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.07.2025 г., 23:19 ч. UTC

Пазарно говорене

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7.07.2025 г., 22:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.07.2025 г., 22:20 ч. UTC

Пазарно говорене

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7.07.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.07.2025 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7.07.2025 г., 20:16 ч. UTC

Пазарно говорене

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7.07.2025 г., 19:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7.07.2025 г., 19:12 ч. UTC

Пазарно говорене

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7.07.2025 г., 18:33 ч. UTC

Пазарно говорене

Gold Flat as Investors Assess Market Direction -- Market Talk

7.07.2025 г., 18:27 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.07.2025 г., 16:53 ч. UTC

Печалби

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7.07.2025 г., 16:30 ч. UTC

Пазарно говорене

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.07.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7.07.2025 г., 15:41 ч. UTC

Пазарно говорене

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7.07.2025 г., 15:41 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.07.2025 г., 15:40 ч. UTC

Пазарно говорене

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7.07.2025 г., 15:30 ч. UTC

Пазарно говорене

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7.07.2025 г., 15:18 ч. UTC

Пазарно говорене

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7.07.2025 г., 15:14 ч. UTC

Придобивния, сливания и поглъщания

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7.07.2025 г., 15:00 ч. UTC

Придобивния, сливания и поглъщания

GSK Completes Acquisition of Efimosfermin

7.07.2025 г., 14:52 ч. UTC

Пазарно говорене

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7.07.2025 г., 14:51 ч. UTC

Пазарно говорене

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7.07.2025 г., 14:45 ч. UTC

Пазарно говорене

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Roivant Sciences Ltd Прогноза

Ценова цел

By TipRanks

36.49% нагоре

12-месечна прогноза

Среден 15 USD  36.49%

Висок 18 USD

Нисък 12 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Roivant Sciences Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

11 / 11.18Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

143 / 375 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.